Annexon, Inc. (ANNX) SEC Filings

Annexon, Inc. reported that director Mark S. Blumenkranz received a grant of 175,000 stock options on August 10, 2026. The options have an exercise price of $5.39 per share and expire on August 10, 2036. According to the vesting terms, 1/36 of the shares vest monthly starting from August 10, 2026, so all 175,000 underlying common shares are scheduled to be fully vested and exercisable on the third anniversary of that date, subject to his continuous service as a director.

Annexon, Inc. director Mark S. Blumenkranz filed an initial statement of beneficial ownership on Form 3. The filing identifies him as a director of Annexon but reports no transactions and no reportable holdings or derivative positions at this time. An Exhibit 24 power of attorney is referenced.

Annexon, Inc. is a clinical-stage biopharmaceutical company developing complement-targeted immunotherapies for neuroinflammatory diseases. For the quarter ended June 30, 2026, it reported a net loss of $55.3 million, compared with $49.2 million a year earlier; the six‑month net loss was $99.5 million versus $103.5 million in 2025.

Research and development expenses were $46.6 million for the quarter and $82.4 million for the first half, down 11% year over year for the six‑month period, while general and administrative expenses rose to $20.9 million for the half, a 24% increase, mainly from higher professional services and stock-based compensation.

Cash, cash equivalents and short-term investments totaled $209.2 million as of June 30, 2026, and operating activities used $94.8 million of cash in the first half. Management states existing liquidity is expected to fund operations into 2028. After quarter-end, Annexon entered a term loan facility of up to $200.0 million, with an initial $50.0 million tranche funded, to further support its late-stage programs tanruprubart in Guillain-Barré Syndrome and vonaprument in geographic atrophy, along with oral candidate ANX1502.

Annexon, Inc. reported second quarter 2026 results while advancing its late-stage neuroinflammatory pipeline. For the quarter ended June 30, 2026, the company recorded a net loss of $55,348 thousand, compared with $49,156 thousand a year earlier, driven by higher research and development and general and administrative expenses. For the first six months of 2026, net loss was $99,490 thousand, modestly improved from $103,512 thousand in 2025.

Cash and cash equivalents were $199,270 thousand and short-term investments were $9,973 thousand as of June 30, 2026, with total assets of $246,068 thousand and stockholders’ equity of $186,061 thousand. Management highlighted a new $200 million credit facility, stating it strengthens the balance sheet and extends the anticipated cash runway into 2028.

Clinically, Annexon expanded its Phase 3 ARCHER II trial of vonaprument in geographic atrophy to add a Month 24 dual primary endpoint alongside the Month 15 endpoint and launched an open-label extension study. The company expects Month 15 primary endpoint assessment in the fourth quarter of 2026 and completion of ARCHER II, including Month 24 analyses, in the third quarter of 2027. A BLA submission for tanruprubart in Guillain-Barré syndrome is expected in the fourth quarter of 2026, and proof-of-concept data for ANX1502 are anticipated in fall 2026.

Annexon, Inc. reported changes to its board of directors. On August 10, 2026, long‑serving director and investor Muneer Satter notified the company of his resignation from the board, the audit committee and as chair of the nominating and corporate governance committee, effective immediately prior to the appointment of a replacement. The company stated that his resignation was not due to any disagreement regarding operations, policies, practices, strategy, management or the board.

On the same date, the board appointed Mark S. Blumenkranz, M.D., M.M.S. as a Class II director, with a term expiring at the 2028 annual meeting of stockholders, and named him to the audit and science and technology committees. Under Annexon’s non‑employee director compensation program, he will receive a $40,000 annual cash retainer and annual stock options for 65,000 shares, and was granted an initial stock option for 175,000 shares under the 2020 Incentive Award Plan.

State Street Corporation has reported beneficial ownership of 9,824,321 shares of Annexon Inc. common stock, representing 6% of the class. These shares are held with no sole voting or dispositive power; State Street reports shared voting power over 9,572,419 shares and shared dispositive power over 9,824,321 shares. The position is held through investment management subsidiaries, including SSGA Funds Management, Inc., State Street Global Advisors entities in Europe and the U.K., and State Street Global Advisors Trust Company. No other person is identified as having rights to more than 5% of the class through this holding, and no filing group or group dissolution is reported. The certification is signed by Elizabeth Schaefer, Senior Vice President and Chief Accounting Officer of State Street Corporation.

Annexon, Inc. reported early results from its ongoing open-label FORWARD study of tanruprubart in Guillain-Barré syndrome (GBS). In the first 10 U.S. and European patients, a single 30 mg/kg intravenous dose was associated with rapid improvement in strength and clinically meaningful reductions in disability within days.

GBS affects approximately 22,000 patients annually across the U.S. and Europe and is linked to an estimated >$20 billion annual U.S. healthcare burden. Annexon plans to use FORWARD data to support a Biologics License Application targeted for Q4 2026, and a Marketing Authorisation Application for tanruprubart is under review by the EMA. Tanruprubart has received Fast Track and Orphan Drug designations in the U.S. and orphan designation in the EU.

Annexon, Inc. entered into a Loan and Security Agreement with Oxford Finance LLC and other lenders providing term loans in an aggregate principal amount of up to $200.0 million. An initial tranche of $50.0 million was funded at closing, with three additional tranches of up to $100.0 million tied to specified milestones and conditions, and a further uncommitted tranche of up to $50.0 million available upon mutual agreement or lender approval. Proceeds may be used for working capital and general business requirements, including advancing the vonaprument and tanruprubart registrational programs.

The loans bear interest at a floating rate equal to the greater of 1-Month CME Term SOFR plus 4.6% or 7.60%. Maturity falls on July 1, 2031 or June 1, 2032, depending on achievement of milestones. Annexon will make interest-only monthly payments until September 1, 2029, potentially extendable to September 1, 2030 or September 1, 2031, after which principal and interest are payable. The loans may be prepaid subject to customary fees, include a final payment fee, and are secured by a security interest in substantially all of Annexon’s assets, with customary covenants and events of default that could accelerate repayment obligations.

BlackRock, Inc. reports beneficial ownership of common stock of ANNEXON INC. BlackRock and certain of its subsidiaries and affiliates collectively hold 13,128,281 shares, representing 8.0% of Annexon’s outstanding common stock.

BlackRock has sole voting power over 12,900,823 shares and sole dispositive power over 13,128,281 shares, with no shared voting or dispositive power. Various underlying clients have the right to receive dividends or sale proceeds from these shares, but no single such person is reported to hold more than five percent of Annexon’s total outstanding common shares. The filing is signed by a Managing Director of BlackRock.